Serena Di Cosimo
University of Milan
203 Papers
815 Citations
Serena Di Cosimo is an academic researcher from University of Milan. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 32, co-authored 133 publications. Previous affiliations of Serena Di Cosimo include Sapienza University of Rome & Novartis.
Chat about Author
Papers
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
José Baselga,José Baselga,Ian Bradbury,Holger Eidtmann,Serena Di Cosimo,Serena Di Cosimo,Evandro de Azambuja,Claudia Aura,Henry L. Gomez,Phuong Dinh,Karine Fauria,Veerle Van Dooren,Gursel Aktan,Aron Goldhirsch,Tsai Wang Chang,Zsolt Horváth,Maria Antonia Coccia-Portugal,Julien Domont,Ling Min Tseng,Georg Kunz,Joohyuk Sohn,Vladimir Semiglazov,Guillermo Lerzo,Marketa Palacova,Volodymyr Probachai,Lajos Pusztai,Michael Untch,Richard D. Gelber,Martine Piccart-Gebhart +28 more
TL;DR: Dual inhibition of Her2 might be a valid approach to treatment of HER2-positive breast cancer in the neoadjuvant setting, and the two anti-HER2 agents given together would be better than single-agent therapy.
1.3K
Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer
Maurizio Scaltriti,Federico Rojo,Alberto Ocaña,Judit Anido,Marta Guzman,Javier Cortes,Serena Di Cosimo,Xavier Matias-Guiu,Santiago Ramón y Cajal,Joaquín Arribas,José Baselga +10 more
TL;DR: Breast tumors that express p95HER2 are resistant to trastuzumab and may require alternative or additional anti-HER2-targeting strategies, and women with HER2-overexpressing breast cancers that express this receptor should be responsive to these agents.
928
NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
Violeta Serra,Benjamin Markman,Maurizio Scaltriti,Pieter Johan Adam Eichhorn,Vanesa Valero,Marta Guzman,Maria Luisa Botero,Elisabeth Llonch,Francesco Atzori,Serena Di Cosimo,Michel Maira,Carlos Garcia-Echeverria,Josep Lluis Parra,Joaquín Arribas,José Baselga +14 more
TL;DR: NVP-BEZ235 inhibits the PI3K/mTOR axis and results in antiproliferative and antitumoral activity in cancer cells with both wild-type and mutated p110-alpha, suggesting that skin may serve as surrogate tissue for pharmacodynamic studies.
780
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
Evandro de Azambuja,Andrew P. Holmes,Martine Piccart-Gebhart,Eileen Holmes,Serena Di Cosimo,Ramona F. Swaby,Michael Untch,Christian Jackisch,István Láng,Ian E. Smith,Frances M. Boyle,Binghe Xu,Carlos H. Barrios,Edith A. Perez,Hatem A. Azim,Sung Bae Kim,Sherko Kuemmel,Chiun-Sheng Huang,Peter Vuylsteke,Ruey Kuen Hsieh,Vera Gorbunova,Alexandru Eniu,Lydia Dreosti,Natalia Tavartkiladze,Richard D. Gelber,Holger Eidtmann,José Baselga +26 more
TL;DR: The NeoALTTO trial showed that 3-year event-free survival was significantly improved for women who achieved pathological complete response compared with those who did not, and the association between pathological complete responded and overall survival was assessed.
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial
Martine Piccart-Gebhart,Eileen Holmes,Jośe Baselga,Evandro de Azambuja,Amylou C. Dueck,Giuseppe Viale,Jo Anne Zujewski,Aron Goldhirsch,A Armour,Kathleen I. Pritchard,Ann E. McCullough,Stella Dolci,Eleanor McFadden,Andrew P. Holmes,Liu Tong-hua,Holger Eidtmann,Phuong Dinh,Serena Di Cosimo,Nadia Harbeck,Sergei Tjulandin,Young-Hyuck Im,Chiun-Sheng Huang,Véronique Diéras,David W. Hillman,Antonio C. Wolff,Christian Jackisch,István Láng,Michael Untch,Ian E. Smith,Frances M. Boyle,Binghe Xu,Henry L. Gomez,Thomas M. Suter,Richard D. Gelber,Edith A. Perez +34 more
TL;DR: Adjuvant treatment that includes L did not significantly improve DFS compared with T alone and added toxicity, and one year of adjuvant T remains standard of care.